Trial
NCT06489340
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
ZyVersa Therapeutics, Inc.
Collaborators
—
Condition
Diabetic Kidney Disease
Intervention
2HPβCD
Why stopped
Withdrawn due to patient enrollment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-25